Patents by Inventor Steve Ruben
Steve Ruben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9090682Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: GrantFiled: December 6, 2013Date of Patent: July 28, 2015Assignee: Celera CorporationInventors: Steve Ruben, Bruno Domon, Candy Lee
-
Publication number: 20150125456Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: October 22, 2014Publication date: May 7, 2015Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Publication number: 20150037820Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Inventors: Charles BIRSE, Steve RUBEN, Marcia LEWIS, Mehdi MESRI
-
Publication number: 20140314770Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: February 5, 2014Publication date: October 23, 2014Applicant: Celera CorporationInventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE
-
Publication number: 20140314768Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: October 23, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Patent number: 8808997Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: GrantFiled: January 12, 2011Date of Patent: August 19, 2014Assignee: Celera CorporationInventors: Charles Birse, Marcia Lewis, Steve Ruben, Mehdi Mesri
-
Publication number: 20140193419Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: July 10, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140178362Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.Type: ApplicationFiled: July 1, 2013Publication date: June 26, 2014Applicant: CELERA CORPORATIONInventors: Charles E. BIRSE, Bruno DOMON, Steve RUBEN, Candy LEE
-
Publication number: 20140099310Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: August 6, 2013Publication date: April 10, 2014Applicant: CELERA CORPORATIONInventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Patent number: 8632987Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: GrantFiled: November 6, 2012Date of Patent: January 21, 2014Assignee: Celera CorporationInventors: Steve Ruben, Bruno Domon, Candy Lee
-
Publication number: 20130315915Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: April 30, 2013Publication date: November 28, 2013Applicant: Celera CorporationInventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Patent number: 8524238Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: March 30, 2012Date of Patent: September 3, 2013Assignee: Celera CorporationInventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal
-
Patent number: 8507213Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.Type: GrantFiled: November 8, 2006Date of Patent: August 13, 2013Assignee: Celera CorporationInventors: Candy Lee, Steve Ruben, Bruno Domon, Charles E. Birse
-
Patent number: 8486392Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: October 8, 2010Date of Patent: July 16, 2013Assignee: Celera CorporationInventors: Steve Ruben, Paul Moore, Tao He, Candy N. Lee, Karen Van Orden
-
Publication number: 20130111613Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: September 17, 2012Publication date: May 2, 2013Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Publication number: 20130078253Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: March 30, 2012Publication date: March 28, 2013Applicant: CELERA CORPORATIONInventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Patent number: 8334106Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: GrantFiled: December 29, 2011Date of Patent: December 18, 2012Assignee: Celera CorporationInventors: Steve Ruben, Candy N. Lee, Bruno Domon
-
Publication number: 20120183552Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: July 15, 2011Publication date: July 19, 2012Applicant: CELERA CORPORATIONInventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE, Yeounjin KIM
-
Publication number: 20120177659Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
-
Patent number: 8168586Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: November 21, 2008Date of Patent: May 1, 2012Assignee: Celera CorporationInventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal